Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | EED | O75530 | 1/20 | 0.41 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.41 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.41 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.41 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31707414 | 0.91 | GPR119 (0.47) | GPR119TGFBR1KDM4EPKMEED | |
| SCHEMBL29641041 | 0.88 | MAPT (0.50) | GPR119NR1H2NR1H3ALDH1A1 | |
| SCHEMBL21933316 | 0.88 | MAPT (0.50) | GPR119NR1H2NR1H3ALDH1A1 | |
| SCHEMBL18921598 | 0.86 | GPR119 (0.50) | GPR119TGFBR1KDM4EPKMNR1H2 | |
| SCHEMBL31707413 | 0.86 | GPR119 (0.50) | GPR119TGFBR1KDM4EPKMEED | |
| SCHEMBL30906239 | 0.84 | MAPT (0.47) | GPR119NR1H2NR1H3ALDH1A1 | |
| SCHEMBL31204447 | 0.83 | MAPT (0.42) | GPR119KDM4ENR1H2NR1H3ALDH1A1 | |
| SCHEMBL21876917 | 0.81 | BRD4 (0.42) | KDM4EALDH1A1 | |
| SCHEMBL25202645 | 0.80 | CYP11B2 (0.41) | GPR119NR1H2NR1H3ALDH1A1 | |
| SCHEMBL22454337 | 0.80 | CYP3A4 (0.47) | GPR119PKMNR1H2NR1H3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | ARVINAS OPERATIONS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | CRBN, KRAS, WEE1 | GPR119 3564/4885TGFBR1 3889/4885KDM4E 1273/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | GPR119 3746/4885TGFBR1 2087/4885KDM4E 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.